Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Epidemiology of chronic myeloid leukaemia (CML).

Rohrbacher M, Hasford J.

Best Pract Res Clin Haematol. 2009 Sep;22(3):295-302. doi: 10.1016/j.beha.2009.07.007. Review.

PMID:
19959081
2.

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers.

Lötsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, Rohrbacher M, Sittl R, Geisslinger G.

Pharmacogenet Genomics. 2009 Jun;19(6):429-36.

PMID:
19514130
3.

Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?

Lötsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmöller J, Geisslinger G.

Pain. 2009 Jul;144(1-2):119-24. doi: 10.1016/j.pain.2009.03.023. Epub 2009 Apr 22.

PMID:
19395173
4.

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.

Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Müller MC, Hasford J, Heimpel H, Hehlmann R.

Leukemia. 2009 Mar;23(3):602-4. doi: 10.1038/leu.2008.245. Epub 2008 Sep 11. No abstract available.

PMID:
18784744
5.

The partial 5-hydroxytryptamine1A receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans.

Oertel BG, Schneider A, Rohrbacher M, Schmidt H, Tegeder I, Geisslinger G, Lötsch J.

Clin Pharmacol Ther. 2007 Jan;81(1):59-68.

PMID:
17186000
6.

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.

von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A.

Br J Clin Pharmacol. 2006 Nov;62(5):552-9.

7.

Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.

Rohrbacher M, Kirchhof A, Geisslinger G, Lötsch J.

Pharmacogenomics. 2006 Oct;7(7):995-1002.

PMID:
17054410
8.

Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.

Rohrbacher M, Kirchhof A, Skarke C, Geisslinger G, Lötsch J.

Pharmacogenomics. 2006 Mar;7(2):167-76.

PMID:
16515396
9.

Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.

Lötsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, Geisslinger G.

Clin Pharmacol Ther. 2006 Jan;79(1):35-48.

PMID:
16413240
10.

The A(-336C) insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women.

Rohrbacher M, Risch A, Kropp S, Chang-Claude J.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):289-90. No abstract available.

Supplemental Content

Loading ...
Support Center